Lexicon has announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic pain (DPNP) at Arrowhead’s 19th Annual Pain Therapeutics Summit, October 13-14 in San Diego, CA.
Discovered using Lexicon’s special approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signalling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behaviour in models of neuropathic pain without affecting opiate pathways.
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives.
